This is the text extract for August Tender Notification; Contact: Notifications, browse documents here.

---

31 August 2011

TENDER RESULTS

The PHARMAC Board (or Chief Executive under Delegated Authority) has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2010/11 Invitation to Tender, dated 2 November 2010 and 2009/10 Invitation to Tender, dated 4 December 2009. As discussed in our 2010 tender consultation document, we are notifying tender decisions as they are made in 2011. This change is to provide maximum notification of upcoming changes to the market, specifically to incumbent suppliers. Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms and Pharmacodes

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by 4pm on the 12th of the month prior to the date of subsidy change. More information and NOPC forms can be found on our website – www.pharmac.govt.nz/schedule.asp. Where a product does not have a current pharmacode, suppliers are required to ensure a pharmacode has been received from the Pharmacy Guild of New Zealand before the 12th of the month prior to the date of listing. PHARMAC cannot list a product (and pharmacies cannot claim) without the correct pharmacode.

Note: This tender notification has been amended as Temozolomide was included in the 2009/10 Tender and therefore has Sole Supply Status and Hospital Supply Status until 30 June 2013, not 30 June 2014.

A450317 - qA18036

Page 1 of 5

---

2010/11 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2014 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows: Chemical Name Presentation; Pack size and type Inj 500 mg; 5 vials Inj 1 g; 5 vials Current New subsidy subsidy and and price price $5.00 $8.00 $3.99 $3.99 Sole supply brand (Supplier) AFT (AFT) AFT (AFT) Date of listing/subsidy change for tender winning brand 1 January 2012 1 January 2012 Date of reference pricing of other listed brands 1 March 2012 1 March 2012 Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting 1 June 2012 1 June 2012 Hospira (Hospira) Hospira (Hospira)

Cefazolin sodium Cefazolin sodium

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

2. Tenders awarded to pharmaceuticals where no brand is listed.

Presentation; Pack size and type 10 µg per ml, 50 ml; 10 prefilled syringes 20 µg per ml, 50 ml; 10 prefilled syringes 10 µg per ml, 50 ml; 10 premixed bags 10 µg per ml, 100 ml; 10 premixed bags Inf 1 mg per ml, 100 ml; 10 premixed bags Hospital Supply Brand (Supplier) Biomed (Biomed) Biomed (Biomed) Biomed (Biomed) Biomed (Biomed) Biomed (Biomed) DV Limit 1% 1% 1% 1% 1%

The decisions were as follows:

Chemical Name Fentanyl Fentanyl Fentanyl Fentanyl Morphine sulphate

Pack price $165.00 $185.00 $210.00 $210.00 $165.00

Listing date 1 October 2011 1 October 2011 1 October 2011 1 October 2011 1 October 2011

Hospital Supply Status date 1 December 2011 1 December 2011 1 December 2011 1 December 2011 1 December 2011

A4503170317 - qA18036

Page 2 of 5

---

3.

Tenders awarded to listed pharmaceuticals where only the current brand is listed.

Chemical Name Morphine sulphate Morphine sulphate Morphine sulphate Presentation; Pack size and type Inj 1 mg per ml, 10 ml; 10 prefilled syringes Inj 1 mg per ml, 50 ml; 10 prefilled syringes Inj 2 mg per ml, 30 ml; 10 prefilled syringes Current pack price $34.50 $59.50 $95.00 New pack price $39.50 $79.50 $135.00 Hospital Supply Brand (Supplier) Biomed (Biomed) Biomed (Biomed) Biomed (Biomed) DV Limit 1% 1% 1% Date of price change 1 October 2011 1 October 2011 1 October 2011 Hospital Supply Status date 1 December 2011

The decisions were as follows:

1 December 2011 1 December 2011

4.

Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

Presentation; Pack size and type Inj 500 mg; 5 vials Inj 1 g; 5 vials Current pack price $5.00 $8.00 New pack price $3.99 $3.99 Hospital Supply Brand (Supplier) AFT (AFT) AFT (AFT) DV Limit 1% 1% Date of listing/price change for tender winning brand 1 January 2012 1 January 2012 Hospital Supply Status date (and delisting of other listed brands) 1 March 2012 1 March 2012 Brand (Supplier) to be delisted Hospira (Hospira) Hospira (Hospira)

The decisions were as follows:

Chemical Name

Cefazolin sodium Cefazolin sodium

A4503170317 - qA18036

Page 3 of 5

---

2009/10 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2013 Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule

5. Tenders awarded to pharmaceuticals where at least one other brand is listed.

The decisions were as follows: Chemical Name Presentation; Pack size and type Cap 5 mg; 5 capsules, bottle Cap 20 mg; 5 capsules, bottle Cap 100 mg; 5 capsules, bottle Cap 250 mg; 5 capsules, bottle Current New subsidy subsidy and and price price $50.00 $170.00 $840.00 $2,100.00 $16.00 $72.00 $350.00 $820.00 Sole supply brand (Supplier) Temacoord (Douglas) Temacoord (Douglas) Temacoord (Douglas) Temacoord (Douglas) Date of listing/subsidy change for tender winning brand 1 January 2012 1 January 2012 1 January 2012 1 January 2012 Date of reference pricing of other listed brands 1 March 2012 1 March 2012 1 March 2012 1 March 2012 Sole Subsidised Brand (Supplier) Supply date (and affected by delisting of other reference pricing listed brands) and delisting 1 June 2012 1 June 2012 1 June 2012 1 June 2012 Temodal (MSD) Temodal (MSD) Temodal (MSD) Temodal (MSD)

Temozolomide Temozolomide Temozolomide Temozolomide

Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule

6. Tenders awarded to listed pharmaceuticals where at least one other brand is listed.

Presentation; Pack size and type Cap 5 mg; 5 capsules, bottle Cap 20 mg; 5 capsules, bottle Cap 100 mg; 5 capsules, bottle Cap 250 mg; 5 capsules, bottle Current pack price $50.00 $170.00 $840.00 $2,100.00 New pack price $16.00 $72.00 $350.00 $820.00 Hospital Supply Brand (Supplier) Temacoord (Douglas) Temacoord (Douglas) Temacoord (Douglas) Temacoord (Douglas) DV Limit 1% 1% 1% 1% Date of listing/price change for tender winning brand 1 January 2012 1 January 2012 1 January 2012 1 January 2012 Hospital Supply Status date (and delisting of other listed brands) 1 March 2012 1 March 2012 1 March 2012 1 March 2012 Brand (Supplier) to be delisted Temodal (MSD) Temodal (MSD) Temodal (MSD) Temodal (MSD)

The decisions were as follows:

Chemical Name

Temozolomide Temozolomide Temozolomide Temozolomide

A4503170317 - qA18036

Page 4 of 5

---

Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2010/11 Invitation to Tender, dated 2 November 2010:

Chemical Name Morphine sulphate Budesonide Budesonide Line Item Inj 1 mg per ml, 30 ml prefilled syringe Metered aqueous nasal spray, 50 µg per dose Metered aqueous nasal spray, 100 µg per dose Chemical Name Beclomethasone dipropionate Beclomethasone dipropionate Iron sucrose Line Item Metered aqueous nasal spray, 50 µg per dose Metered aqueous nasal spray, 100 µg per dose Inj 20 mg per ml

The PHARMAC Board (or Chief Executive under Delegated Authority) resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in the 2009/10 Invitation To Tender, dated 4 December 2009:

Chemical Name Levonorgestrel Line Item Tab 750 µg – 1.5 mg Chemical Name Line Item

For products included in the 2009/10 Invitation to Tender and 2010/11 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or Chief Executive) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification please contact PHARMAC on 0800 66 00 50.

A4503170317 - qA18036

Page 5 of 5